Clarity Pharmaceuticals Ltd (ASX: CU6)
Australia
· Delayed Price · Currency is AUD | Market Cap | 1.94B |
| Revenue (ttm) | 11.51M |
| Net Income (ttm) | -42.32M |
| Shares Out | 320.21M |
| EPS (ttm) | -0.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,237,730 |
| Open | 6.01 |
| Previous Close | 6.06 |
| Day's Range | 5.90 - 6.14 |
| 52-Week Range | 1.26 - 8.98 |
| Beta | 1.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 29, 2024 |
About Clarity Pharmaceuticals
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA,... [Read more]
Financial Performance
In 2024, Clarity Pharmaceuticals's revenue was 11.51 million, an increase of 17.41% compared to the previous year's 9.80 million. Losses were -42.32 million, 72.0% more than in 2023.
Financial StatementsNews
Rising Shares at Clarity Pharmaceuticals as it Launches Second Phase III Trial and Promotes Michelle Parker to CEO
Biotech firm Clarity Pharmaceuticals is preparing to initiate a second Phase III clinical trial for its prostate cancer diagnostic product, 64Cu-SAR-bisPSMA, after receiving positive feedback from the...
Three ASX companies jockeying to be the next biotech winners
Clarity Pharmaceuticals reports it eliminated prostate cancer in a patient; LTR Pharma wants to sell nasal viagra; and Opthea has clinical trial results soon.